Found: 13
Select item for more details and to access through your institution.
Preventable and potentially preventable serious adverse reactions induced by oral protein kinase inhibitors through a database of adverse drug reaction reports.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 2, p. 229, doi. 10.1007/s11523-014-0328-7
- By:
- Publication type:
- Article
The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 2, p. 235, doi. 10.1007/s11523-014-0329-6
- By:
- Publication type:
- Article
Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 2, p. 179, doi. 10.1007/s11523-014-0330-0
- By:
- Publication type:
- Article
Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 2, p. 247, doi. 10.1007/s11523-014-0332-y
- By:
- Publication type:
- Article
Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 2, p. 199, doi. 10.1007/s11523-014-0333-x
- By:
- Publication type:
- Article
Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 2, p. 189, doi. 10.1007/s11523-014-0334-9
- By:
- Publication type:
- Article
Decreased mRNA expression of GATA1 and GATA2 is associated with tumor aggressiveness and poor outcome in clear cell renal cell carcinoma.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 2, p. 267, doi. 10.1007/s11523-014-0335-8
- By:
- Publication type:
- Article
Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 2, p. 255, doi. 10.1007/s11523-014-0336-7
- By:
- Publication type:
- Article
Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 2, p. 303, doi. 10.1007/s11523-015-0367-8
- By:
- Publication type:
- Article
Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 2, p. 215, doi. 10.1007/s11523-014-0323-z
- By:
- Publication type:
- Article
Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).
- Published in:
- Targeted Oncology, 2015, v. 10, n. 2, p. 277, doi. 10.1007/s11523-014-0337-6
- By:
- Publication type:
- Article
Combination of individualized local control and target-specific agent to improve unresectable liver cancer managements: a matched case-control study.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 2, p. 287, doi. 10.1007/s11523-014-0338-5
- By:
- Publication type:
- Article
Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 2, p. 297, doi. 10.1007/s11523-014-0350-9
- By:
- Publication type:
- Article